WM1552C - Cell Line (ID:50568)

Name: WM1552C
Alternative Names:
Alternative ID: CLO_0009614
Parent Cell Line:
Reference Source: ATCC CRL-2808
Organism: Homo sapiens
Organ: skin
Cell Type:
Details of Cell Type:
Donor Sex: male
Donor Age:
Donor Ethnicity:
Donor Health Status:
Disease: DOID:1909, malignant melanoma
Details of Disease:
Production Details:
Genetic Modification(s): none
Known Mutations:
Citation Information for Mutations: COSS1299078
Verification Reference Profile:
Growth Properties: adherent
Recommended Culture Conditions: From MGH/CMT as specified by cell provider: 2% Tumor Medium (Tu2%) containing a 4:1 mixture of MCDB 153 medium with 1.5 g/L sodium bicarbonate and Leibovitz's L-15 medium with 2 mM L-glutamine supplemented with 0.005 mg/ml bovine insulin, 1.68 mM CaCl2, and 2% fetal bovine serum. Protocol: Remove and discard culture medium. Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor. Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes). Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal. Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting. Add appropriate aliquots of the cell suspension to new culture vessels. An inoculum of 5 X 10(3) to 7 X 10(3) viable cells/cm2 is recommended. . Incubate cultures at 37°C. Subcultivation ratio: A subcultivation of 1:3 to 1:4 is recommended
Relevant Citations:
Usage Note:
Date Publicly Available: 2012-07-31
Most Recent Update: 2016-04-04

Batch Information for HMSL50568-1:

HMS LINCS Batch ID: 50568-1
Provider: Nathan Moerke (Harvard Medical School)
Provider Catalog ID:
Provider Batch ID:
Source Information: Obtained by Nathan Moerke (Harvard Medical School) from the Center for Molecular Therapeutics (CMT; Massachusetts General Hospital) (contact: Cyril Benes) and distributed to Mohammad Fallahi-Sichani in 2012
Date Received: 2012
HMS QC Outcome:
Transient Modification(s):
Date Publicly Available: 2012-07-31
Most Recent Update: 2015-06-29